IN THE CLAIMS

I claim

[C1] A method of stimulating an immune response in a virally infected individual, the method comprising:

providing an imidazoquinolinamine formulation;

disposing an amount of the imidazoquinolinamine formulation into a first nare of a virally infected individual; and

covering at least a portion of the internal surface of the individual's first nare with a portion of the amount of the imidazoquinolinamine in said nare.

[C2] The method of claim 1, wherein the imidazoquinolinamine formulation's active ingredient is selected from the group consisting of imiquimod and resiquimod.

[C3] The method of claim 1, wherein the imidazoquinolinamine formulation is disposed using a device selected from the group consisting of a swab, syringe, spray nozzle, and a drip applicator.

[C4] The method of claim 1, wherein the imidazoquinolinamine formulation comprises imiquimod as an active ingredient in the amount of about 12 mg.

[C5] The method of claim 1, wherein the imidazoquinolinamine formulation comprises resiquimod as an active ingredient in the amount of about 12 mg.

[C6] The method of claim 1, wherein the imidazoquinolinamine formulation is selected from a group consisting of a cream, gel, liquid, paste, aerosol, and an emulsion.

[C7] The method of claim 1, wherein about 15 minutes prior to disposing the imidazoquinolinamine formulation, the first nare is treated with a decongestant.

[C8] The method of claim 7, wherein the decongestant is Neosynepherine.

[C9] The method of claim 1, wherein the individual is infected with viral rhinitis.

[C10] The method of claim 1 further comprising providing the imidazoquinolinamine formulation every twelve hours until relief from cold symptoms is obtained.

[C11] The method of claim 1, wherein the imidazoquinolinamine formulation is applied within twenty four hours after an appearance of first cold symptoms.